Drug Profile
Genz 644470
Alternative Names: Advanced phosphate binder; Genz-644470Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class
- Mechanism of Action Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperphosphataemia
Most Recent Events
- 19 Nov 2009 Discontinued - Phase-II for Hyperphosphataemia in USA (PO)
- 25 Feb 2009 Preclinical trials in Hyperphosphataemia in USA (unspecified route)